London’s status as a global hub for pharmaceutical research is under threat as two major companies, MSD and Eli Lilly, have halted significant projects in the city. MSD has completely ditched its landmark £1bn research center, while Eli Lilly has confirmed it will not sign the lease for a new “gateway lab” until the UK’s commercial climate for medicines improves.
These decisions reflect a broader crisis of confidence in the UK market. A senior executive from another pharmaceutical giant, Sanofi, recently branded the country a “terrible place to sell medicines.” Sanofi has backed this sentiment with action, reducing its UK clinical trials by 50% and transferring work from its former Cambridge labs to the US.
The root causes cited by the industry are financial and political. The UK’s spending on medicines is significantly lower than its European and American counterparts, making it a less attractive market. This is compounded by outdated pricing regulations and a revenue repayment scheme that the industry considers punitive.
Experts are now warning of a domino effect, with other companies likely to de-prioritize the UK for future investment. The government is facing urgent calls to reopen negotiations with the industry and present a new, more competitive deal on drug pricing and market access to prevent further damage to its “crown jewel” life sciences sector.